You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


EU expands scope of Imbruvica to include untreated CLL patients

The European Commission (EC) has expanded the marketing authorisation for Janssen’s Imbruvica (ibrutinib) to include treatment na├»ve patients with chronic lymphocytic leukaemia (CLL).